Form D · Other Health Care
Eikonizo Therapeutics, Inc.
Beverly, MA · CIK 0001735756
Offering snapshot reported May 16, 2018 · SEC filing
- Reported sold
- $371K Offering amount: $841K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 15, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 16, 2018 | Initial | $371,352 | No comparison | 1 | SEC filing |
| Apr 17, 2018 | Initial | $2,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-312582
Source: Form D, filed May 16, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kevin Kinsella | Director |
| Janice Kranz | Director, Executive |
| William Shaw | Director, Executive |
| Stacie Weninger | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
996 Hale Street
Beverly, MA, 01915
Beverly, MA, 01915